Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0007095 (
carcinoid
)
6,990
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Histidine decarboxylase
is one of the enzymes of the amine precursor uptake and decarboxylation system and is known to be distributed in mast cells and enterochromaffin-like cells. With the hypothesis that histidine decarboxylase expression is a marker for neuroendocrine differentiation, we studied the immunoreactivity of histidine decarboxylase in neuroendocrine cells and tumors of the thyroid gland, adrenal medulla, lung, and gastrointestinal tract. Formalin-fixed paraffin sections were subjected to immunohistochemistry using anti-histidine decarboxylase antibody, and the sensitivity and specificity were compared with those of conventional neuroendocrine markers (CD56, chromogranin A, synaptophysin, and neuron-specific enolase). Enterochromaffin or enterochromaffin-like cells, adrenal chromaffin cells, and thyroid C-cells were positive for histidine decarboxylase, and related tumors (
carcinoid
tumor, pheochromocytoma, medullary carcinoma) showed a high percentage of positive staining. Furthermore, we used the antibody to distinguish small cell lung carcinoma from non-neuroendocrine lung carcinoma and also to detect neuroendocrine differentiation in large-cell neuroendocrine carcinoma and gastrointestinal small-cell carcinoma. The anti-histidine decarboxylase antibody stained most small cell lung carcinoma (18 of 23, sensitivity 0.78), and was rarely reactive with non-neuroendocrine lung tumors (2 of 44; specificity, 0.95). These values were close to those obtained from CD56 staining (sensitivity/specificity, 0.87/0.98).
Histidine decarboxylase
was also positive for 6 of 12 large cell neuroendocrine carcinomas and 4 of 7 gastrointestinal small cell carcinomas. In conclusion, we demonstrated that histidine decarboxylase is useful to distinguish between small cell lung carcinoma and non-neuroendocrine carcinoma and to demonstrate neuroendocrine differentiation.
...
PMID:Histidine decarboxylase expression as a new sensitive and specific marker for small cell lung carcinoma. 1252 16
Histidine decarboxylase
(
HDC
) is an enzyme for decarboxylating l-histidine to histamine and is expressed in various types of cells including neuroendocrine tumors. Recent findings have demonstrated a high percentage of
HDC
immunoreactivity in many neuroendocrine tumors, including
carcinoid
tumors, small cell carcinomas of the lung, pheochromocytomas, and medullary carcinomas of the thyroid.
HDC
immunostaining was applied to pancreatic islet cells and related tumors to explore possible expression of
HDC
as a wide spectrum marker for neuroendocrine differentiation. A total of 24 cases (22 pancreatic endocrine neoplasms, one small cell carcinoma of the pancreas, and one mixed exocrine-endocrine carcinoma) along with normal pancreatic tissue were immunostained with the anti-
HDC
antibody. In a normal pancreas, a double immunostaining revealed possible colocalization of
HDC
with glucagon- or insulin-positive cells in the islets. Seventeen of 22 pancreatic endocrine neoplasms (77%) were found to be positive for
HDC
, and no distinct relation to hormonal activity was observed. One small cell carcinoma was strongly positive to
HDC
. One non-functional tumor with mixed exocrine and endocrine components showed a diffuse positive immunostaining for
HDC
, and some neoplastic glucagon- or somatostatin (SRIF)-positive cells coexpressed
HDC
. In conclusion, we demonstrated that the majority of pancreatic endocrine tumors expressed
HDC
, and we suggest that
HDC
is a wider new marker for neuroendocrine differentiation.
...
PMID:Histidine decarboxylase expression in pancreatic endocrine cells and related tumors. 1514 99